Based on the information available, it does not appear that you can directly expedite the application processing for Vascepa, or any other drug, through the U.S. Food and Drug Administration (FDA) [1]. The FDA has established procedures and guidelines for the approval of drugs, which include rigorous testing and clinical trials to ensure safety and efficacy [1].

However, there are programs and designations that can potentially expedite the development and review of new drugs, including those that treat serious or life-threatening conditions [1]. For example, the FDA offers the Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval programs [1]. To be considered for these programs, a drug must meet certain criteria and the sponsor (usually the drug manufacturer) must submit a request to the FDA [1].

It is important to note that these programs are designed to expedite the development and review of new drugs, not to expedite the application process [1]. The FDA still thoroughly reviews all applications and data submitted for a new drug, regardless of whether it is part of an expedited program or not [1].

In the case of Vascepa, it was approved by the FDA in December 2019 for the treatment of patients with severe hypertriglyceridemia [2]. It is unclear if Vascepa was part of any expedited programs during its development and review process [2].

In summary, while there are programs and designations that can potentially expedite the development and review of new drugs, it does not appear that you can directly expedite the application processing for a drug like Vascepa. It is ultimately up to the FDA to determine the timeline for the review and approval of new drugs.

Sources:
[1] U.S. Food and Drug Administration. "Expedited Programs for Serious Conditions." <https://www.fda.gov/patients/learn-about-drug-and-device-approval-process/expedited-programs-serious-conditions>.
[2] DrugPatentWatch. "Vascepa (Icosapent Ethyl)." <https://www.drugpatentwatch.com/drugs/vascepa>.